ALMR — Alamar Biosciences, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 2104204 ·
Last close
$25.91
Market Cap
$1.80B
52W High
$39.61
52W Low
$18.85
ADV30
529,354
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 29,427,000 | 17,718,000 | -13,532,000 | -13,199,000 | 390,975,000 | 132,969,000 | 78,118,000 |
| Mar 2026 | 26,035,000 | 14,457,000 | -12,347,000 | -21,325,000 | 186,451,000 | 64,586,000 | 364,522,000 |
| Jun 2025 | 16,162,000 | 8,581,000 | -7,919,000 | -7,023,000 | — | — | — |
| Mar 2025 | 13,091,000 | 6,389,000 | -8,553,000 | -7,659,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-33,415,000
Investing CF
$16,240,000
Financing CF
$56,004,000
CapEx
$-1,760,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.43
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-190,100,000
Inventory
$39,931,000
Receivables
$19,524,000
ST Investments
—
EBIT TTM
$-28,251,000
Pretax Income TTM
$-28,520,000
Interest Exp TTM
$269,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$100,420,000
EBITDA
$-37,483,000
Free Cash Flow
—
Enterprise Value
$1,736,718,208
Total Cash
$250,052,000
Total Debt
$51,406,000
Shares Out
69,392,766
Trailing EPS
$-0.72
Book Value
$4.51
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 74,211,000 | -31,334,000 | -29,819,000 | 139,992,000 | 298,946,000 | -158,954,000 | -53,608,000 |
| Dec 2024 | 25,142,000 | -49,568,000 | -47,073,000 | 149,511,000 | 282,922,000 | -133,411,000 | -55,214,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$186,451,000
Forward EPS
$-0.54
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| USA | LIBERTY ALL STAR EQUITY FUND | $1.81B | $5.86 | — |
| CMPR | CIMPRESS plc | $1.81B | $74.28 | — |
| GAB | GABELLI EQUITY TRUST INC | $1.79B | $5.20 | — |
| SPB | Spectrum Brands Holdings, Inc. | $1.78B | $77.58 | — |
| GDV-PH | GABELLI DIVIDEND & INCOME TRUST | $1.81B | $22.01 | — |
News headlines (Yahoo Finance, 1h cache)
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
2026-10-08 20:05 · Yahoo
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
2026-10-05 20:05 · Yahoo
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
2026-09-01 20:05 · Yahoo
Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript
2026-08-18 00:14 · Yahoo
Alamar Biosciences Inc (ALMR) (Q2 2026) Earnings Call Highlights: Revenue Surges 82% on 147% ...
2026-08-11 05:02 · Yahoo
Alamar Biosciences (ALMR) Stock Trades At A Premium To Its Sales
2026-08-11 01:08 · Yahoo
Alamar Biosciences Q2 Earnings Call Highlights
2026-08-10 22:04 · Yahoo
Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
2026-08-10 20:05 · Yahoo
Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
2026-08-10 20:03 · Yahoo
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
2026-07-28 20:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.